Company Profile · Healthcare

Xiamen Amoytop Biotech Co Ltd

688278 · Shanghai

Country: China
Employees: 3,640
Website: www.amoytop.com

Buffett Score

66/100

Strong

Financial snapshot

Market capCN¥21.59B

Revenue (TTM)CN¥4.02B

EBITDACN¥1.42B

Profit margin26.85%

ROE36.86%

P/E (TTM)20.11

Forward P/E0

EPSCN¥2.63

Dividend yield1.21%

52-week rangeCN¥48.88 – CN¥89.65

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

About the company

Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China and internationally. It offers various drug products, including pegsomatropin injection, pegfilgrastim injection, molgramostim, filgrastim, and oprelvekin; active pharmaceutical ingredients (APIs); and reagents to treat viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is headquartered in Xiamen, China.

Background

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.

Research on this stock

No reports on this stock in your language yet.